Literature DB >> 9793264

Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma.

M Pérez-Encinas, M Villamayor, A Campos, S González, J L Bello.   

Abstract

We studied the value of soluble CD25, CD8, CD23, CD54 and CD44 serum levels as tumor burden markers in lymphoma. Soluble CD25 compared with the others sCD and the usual serum factors (albumin, lactate dehydrogenase, beta 2-microglobulin, uric acid and C-reactive protein), showed the strongest correlation with the Ann Arbor stage and the number of affected localizations. sCD25 level is the most sensitive serum marker for tumor burden in lymphoma.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9793264

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  3 in total

1.  Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies.

Authors:  Kai Lehmberg; Kim E Nichols; Jan-Inge Henter; Michael Girschikofsky; Tatiana Greenwood; Michael Jordan; Ashish Kumar; Milen Minkov; Paul La Rosée; Sheila Weitzman
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

2.  T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.

Authors:  Camilla A Lindqvist; Lisa H Christiansson; Bengt Simonsson; Gunilla Enblad; Ulla Olsson-Strömberg; Angelica S I Loskog
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

3.  Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.

Authors:  Lisa Christiansson; Stina Söderlund; Emma Svensson; Satu Mustjoki; Mats Bengtsson; Bengt Simonsson; Ulla Olsson-Strömberg; Angelica S I Loskog
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.